about
Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcomeAffinity-based proteomics reveal cancer-specific networks coordinated by Hsp90Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubesCerenkov luminescence imaging of medical isotopes.Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PETCopper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy.Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumabStandardized methods for the production of high specific-activity zirconium-89.Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell cUnderscoring the influence of inorganic chemistry on nuclear imaging with radiometals.89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternativesSmall animal imaging. current technology and perspectives for oncological imaging.The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.The next generation of positron emission tomography radiopharmaceuticals in oncology.Improved synthesis of 2'-deoxy-2'-[18F]-fluoro-1-beta-D-arabinofuranosyl-5-iodouracil ([18F]-FIAU).A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomyNitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes.Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivoFully-automated synthesis of 16β-(18)F-fluoro-5α-dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer.Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.PET imaging with ⁸⁹Zr: from radiochemistry to the clinicPET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein NanoparticlesApplying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins.Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.(89)Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancerRadiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review.Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses.Antilipolytic drug boosts glucose metabolism in prostate cancer.Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy.Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studiesSandmeyer reaction repurposed for the site-selective, non-oxidizing radioiodination of fully-deprotected peptides: studies on the endogenous opioid peptide α-neoendorphin.Imaging tumor burden in the brain with 89Zr-transferrinLow incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy.Clickable bifunctional radiometal chelates for peptide labeling
P50
Q27318509-10207DDC-E575-4FEE-B8DB-D4AB2C1CFFEBQ28249103-7B06E1AD-2F12-4251-9BBA-D07B82003976Q28384090-D7953339-CB46-4B8A-9433-A78794015447Q30499280-A11CA00A-EB58-4E96-A840-363B3912B32FQ30643770-57D71F60-9952-4653-BC22-DF6D583CD014Q33335764-FB543E49-7AB6-43E4-98F9-6A21FD0DDB82Q33527397-31EBF83C-1D28-44EB-ACA4-E3E874DC92B9Q33527397-57444852-7C5D-418A-8B1E-4F19DF852C7FQ33685309-39240454-7EEE-4B05-A22B-8822A6358FD9Q33812606-64900D2C-C4FB-45CF-85D1-6CDCB9827250Q33995700-6D31D752-8643-49DC-B65D-839D1AB733D0Q34119201-695E4572-796A-4107-8355-8162A6A11B7DQ34389457-12E17E8D-9037-4AE6-86EA-0FE12CCD8956Q34473460-8A218C3D-1014-4385-BD01-D6CB44018974Q34975027-550BBB4F-6697-4FE2-8353-6C4DE8153E61Q35133494-CEC02758-84D7-4C26-B4D7-B0BB7EC17BDBQ35525690-1D5A221C-CDD7-45CE-AC60-4AD8EF914E1EQ35541289-D4732727-1C36-495A-8127-FC4E6EC5AC2EQ35544056-A221C4D3-9770-4131-8EF7-F6F26ED8AEBBQ35545523-F52A144A-0EB4-40C2-9327-6E29181B86C6Q35565660-8A339B39-0A56-4408-8C25-6ACFDBCA73C4Q35606075-883B25FE-5C83-4097-87CA-CBD9B97F0FCFQ35931391-15EE5D67-1F65-4B25-BC05-20D4283760C1Q35956405-83226283-3D58-4D0C-97E8-D77FCC11CFCEQ36418274-FA7CC963-20DB-46D5-B5DE-111E0E76B1F0Q36435260-38C2B3FB-4145-434A-8068-AE7F6158C186Q36454584-23F0A78E-2D20-440B-80DF-5F29CADCF724Q36533549-C55464E0-6B46-4508-BA7B-2EB46D7E1086Q36536355-E0F47879-3B30-4561-B328-44A7930B9B0BQ36580750-4406C646-E461-4D13-80E7-2F601FA2B493Q36625800-3A33A8D1-8A80-4AED-98E8-FC062D01D618Q36654876-8F95EE07-12DB-44AC-BAC5-DA11F6C2FDD1Q36707388-E2C98538-4277-4286-BBD8-3F9F0F5345D7Q36855892-5CC29683-917E-42A5-A607-A6E3DEAA442FQ36871763-027E8310-BB26-4884-B986-26A063579776Q37024507-A832AE4D-B69D-4C6D-90F4-07C535C821A3Q37033947-277B893C-4A77-4D3F-9E17-1DF0B246381CQ37049634-39D6979E-85CC-462B-9D4E-355EC9CA95A7Q37106244-0661EE17-436D-41E6-8E49-50F7DC046001Q37114081-78BC6C26-2321-4FBC-A21E-C8B8CB692891
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jason S. Lewis
@ast
Jason S. Lewis
@en
Jason S. Lewis
@es
Jason S. Lewis
@nl
Jason S. Lewis
@sl
جايسون إس. لويس
@ar
type
label
Jason S. Lewis
@ast
Jason S. Lewis
@en
Jason S. Lewis
@es
Jason S. Lewis
@nl
Jason S. Lewis
@sl
جايسون إس. لويس
@ar
prefLabel
Jason S. Lewis
@ast
Jason S. Lewis
@en
Jason S. Lewis
@es
Jason S. Lewis
@nl
Jason S. Lewis
@sl
جايسون إس. لويس
@ar
P106
P1153
26643450800
P21
P31
P496
0000-0001-7065-4534